 CytoDyns main product candidate is Vyrologix, an injectable antibody that shows promise as an anti-viral agent The company is preparing to release data from a Phase 2b3 coronavirus study Two Phase 3 HIV trials have been completed What CytoDyn does: CytoDyn Inc OTCMKTS:CYDY, a Vancouver, Washington-based late-stage biotechnology company, is developing Vyrologix leronlimab or PRO 140 to battle multiple diseases. Most significantly, it is working to develop a significant advance in HIV treatment beyond the AIDS cocktail combination of pills that has kept millions of people alive since the mid-1990s. 